Information Provided By: 
Fly News Breaks for September 30, 2016
HZNP
Sep 30, 2016 | 08:10 EDT
After the U.S. Patent and Trademark Office ruled that Horizon Pharma's '215 patent for Ravicti is unpatentable, JMP Securities analyst Donald Ellis says the news is not material. He says that Ravicti still has orphan drug exclusivity until 2020, and that the company has five other patents on the drug that will last until 2032. He recommends buying Horizon on any weakness.
News For HZNP From the Last 2 Days
There are no results for your query HZNP
